Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2921142 | Heart, Lung and Circulation | 2008 | 12 Pages |
Abstract
Future improvements in lung cancer survival are likely to come from delineating its putative oncogenic pathways. The development of microarray technology to perform thousands of simultaneous genetic experiments and the linking of this to clinical information is an imperative for refining our current treatments and developing new ones. This paper reviews the state of this research, describes a typical microarray experiment and the implications for diagnosis and treatment of non-small cell lung cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Genni M. Newnham, David M. Thomas, Sue Anne McLachlan, Gavin Wright, Matthew Conron,